Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.
Roche And Zealand Team Up To Develop Petrelintide
Roche partnered with Zealand Pharma to co-develop and co-commercialize petrelintide, a novel amylin analog. Roche gains the most advanced amylin analog that is available and strengthens its obesity pipeline as petrelintide can be used as monotherapy and in combination with Roche's existing obesity candidates. Zealand Pharma gains substantial upfront cash, significant potential milestones, and a strong partner for global commercialization, and it also gets upside from petrelintide's use with Roche's candidates.
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an obesity candidate.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate. Shares of Zealand Pharma jumped as much as 29% shortly after the announcement, while Roche added 4.6%.
Roche takes big step in weight-loss field with $5.3 billion deal.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.
Roche to develop, commercialize obesity drug with Zealand Pharma
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
David Roche: ‘NATO is dead' and Europe defense spending needs to increase
Quantum Strategy's David Roche says Europe's defense spending needs to increase by at least $200 billion as he discusses the clash between U.S. President Donald Trump and Ukrainian President Volodymyr Zelenskyy.
David Roche: Germany's coalition government, a 'bumpy ride' going in the right direction
David Roche of Quantum Strategy discusses his optimism for the new German government following their recent elections. He believes the new government will be able enact reforms both domestically and on an EU level.
Roche: Sustainable Sales Growth, Margin Leverage, And Supportive Late-Stage Pipeline
Q4 results reinforce our positive outlook on Roche, highlighting the company's resilience and strategic advancements. Solid performance of Ocrevus and Vabysmo are key drivers of near-term top-line sales. Roche also unveiled a new class of next-generation sequencing technology. Roche's late-stage pipeline supports our belief that there is still room for growth. With a solid balance sheet and a valuation discount, this company is a buy.
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche Holding AG released its Q4 and full-year 2024 earnings yesterday. I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets. Sales were up ~7%, and core EPS grew in the double-digit percentages. Roche had 16 “blockbuster” drugs in 2024, but some face patent expirations in the near-to-medium term, while other, newer products are expected to offset any losses.
